Myriad's melanoma Dx launch continues aggressive test rollout

Myriad Genetics ($MYGN) is rolling out a new melanoma skin biopsy test in the U.S. and will begin a similar effort in "key European markets" starting in early 2014. MyPath Melanoma is the Utah company's third major diagnostics test rollout this fall. Myriad has also started selling its myPlan prognostic test for patients diagnosed with early-stage lung cancer. Also new to the market is its myRisk Hereditary Cancer test, which screens for 25 different genes linked to eight different cancers. Melanoma can be hard to definitively diagnose, and the new Myriad test is designed to help physicians better assess whether a lesion is a malignant or benign growth. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.